CTLA4 and cancer: To date the majority of clinical trials in all cancers including OAC have largely focussed on testing the efficacy of blocking PD-1 and CTLA-4 IC pathways, despite the vast array of potentially targetable ICs expressed on the surfaces of T cells [8], [9], [10], [11].